This is an international website for the GEOMETRY clinical trial program and is intended for health care professionals outside the United States. Please contact your local Novartis representative for the latest information specific to your country.

For health care professionals outside the US.

GEOMETRY Global Evaluation Of MET inhibition’s Role in oncologY—A program of clinical research sponsored by Novartis

The GEOMETRY clinical trial programGEOMETRY is a group of clinical trials designed to study an investigational treatment for malignancies that harbor mesenchymal-epithelial transition (MET) dysregulation, including advanced non-small cell lung cancer (NSCLC).The goal of the GEOMETRY program is to determine the possible treatment benefits and the safety of capmatinib (INC280), an oral c-MET inhibitor.

Incidence of c-MET amplification and c-MET mutation in NSCLC1-4

*Patients with adenocarcinoma with c-MET mutation leading to exon 14 alterations.3,4

Study design5,6Patients are divided into 5 cohorts depending on c-MET gene copy number (GCN) or c-MET dysregulation (amplification or mutation). See the schema below:

End points Primary end point5Overall response rateTrial definition: The proportion of patients with a best overall response defined as complete response (CR) or partial response (PR) by Blinded Independent Review Committee (BIRC) assessment per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.Key secondary end point5Duration of responseTrial definition: The time from the date of the first documented CR or PR by BIRC per RECIST 1.1 to the first documented progression or death due to any cause for patients with PR or CR.Other secondary end points5

To be eligible for Cohorts 1-4, patients must have failed 1 or 2 prior lines of systemic therapy for advanced or metastatic disease

To be eligible for Cohort 5, patients must not have received any systemic therapy for advanced or metastatic disease

At least 1 measurable lesion as defined by RECIST 1.1

Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤1 (Common Terminology Criteria for Adverse Events v 4.03). Patients with any grade of alopecia are allowed to enter the trial

Patients must have adequate organ function

Eastern Cooperative Oncology Group performance status of 0 or 1. Details and other protocol-defined inclusion criteria may apply

Exclusion criteria5

Prior treatment with crizotinib or any other c-MET or hepatocyte growth factor inhibitor

Capmatinib (INC280) is an investigational compound. Efficacy and safety have not been established. There is no guarantee that it will become commercially available.

The information on this site is not country-specific and may contain information that is different from where you practice. Please contact your local Novartis medical representative for the latest information specific to your country.